Skip to main content
Medicine logoLink to Medicine
. 2017 Jul 21;96(29):e7644. doi: 10.1097/MD.0000000000007644

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report: Erratum

PMCID: PMC5521951  PMID: 31305693

In the article, “Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report”,[1] which appeared in Volume 96, Issue 21 of Medicine, “Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China” should have appeared as “Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.”

Reference

  • [1].Liang J-Y, Tong F, Gu F-F. Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report. Medicine. 2017. 96:e6985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES